NovaTarg’s liver selective AMPK activators provide new opportunities in the treatment of metabolic diseases:
Worldwide prevalence of diabetes among adults (20-79 years) is about 6.4% and is estimated to increase to 7.7% by 2030, which represents 439 million adults. Diabetes is becoming one of the leading causes of death in the US with expenditure of approximately 1 in 5 healthcare dollars caring for somebody with diabetes.
Despite the recent introduction of new classes of treatments for Type 2 Diabetes (T2D), the availability of effective medicines is still limited by their safety and efficacy. This is exemplified by the fact that two-thirds of patients receiving medication for T2D in Europe and the US do not achieve their therapeutic goals. Additional first-line therapy represents a significant unmet medical need for these patients
NovaTarg’s approach to liver selective AMPK activators is designed to deliver this new first-line therapy product profile and is on track to select a drug candidate by mid-2013. Such a drug will control hepatic glucose output, as well as regulating liver-derived lipid safely in patients suffering impaired renal function.
The Type 2 Diabetes market is of considerable size that an innovative medicine such as NovaTarg’s will have appreciable value. Sales of drugs to treat Type 2 Diabetes in seven major markets are set to nearly double by 2020, reaching almost $45 billion from 2010’s total of $23.4 billion.
NASH (non-alcoholic steato-hepatitis) and NAFLD (non-alcoholic fatty liver disease) are serious liver diseases that lead to cirrhosis, liver failure and ultimately HCC. No therapies are approved for these indications. However, the NovaTarg approach to liver targeted AMPK activators is anticipated to produce compounds that will block liver lipid production and have a major impact on diseases driven by hepatic steatosis.